Author of

• 13707

  +

  P1.06 - Poster Session/ Screening and Early Detection (ID 218)

  • Event: WCLC 2015
  • Type: Poster
  • Track: Screening and Early Detection
  • Presentations: 1
  • Moderators:
  • Coordinates: 9/07/2015, 09:30 - 17:00, Exhibit Hall (Hall B+C)

  • 13713

    +

    P1.06-006 - Metabolomics by NMR Facilitates the Non-Invasive Diagnosis and Staging of NSCLC (ID 1374)

    09:30 - 17:00  |  Author(s): A. Blasco
    • Abstract
    • Slides

    Background:
    Lung cancer (LC) is the most common cause of cancer death worldwide. At present, the diagnosis is primarily based on symptoms and detection occurs at late stages, thus resulting in a very poor prognosis. If the diagnosis could be shifted to early stages, then the overall morbidity for this disease could be dramatically altered. Metabolomics, an analytical platform used in combination with statistical techniques, has been shown to be a very powerful approach for the understanding of biological pathways involved in the onset and progression of diseases. The objective of this study was to identify, using metabolomics by NMR, a set of specific metabolites that could be used for LC screening in the clinical context.
    
    Methods:
    Metabolic profiles corresponding to a training set of serum samples from early-stage (n = 66) and advanced-stage (n = 69) NSCLC patients were obtained using [1]H-NMR spectroscopy. A matched control set of 71 serum samples from healthy subjects was also included. Furthermore, NMR experiments were also performed for an external validation set consisting of 20 early-stage and 20 advanced-stage NSCLC patients, 13 healthy individuals, and 27 benign pulmonary disease patients (BPD).
    
    Results:
    Multivariate statistical modeling of the data revealed that the serum of NSCLC patients, when compared with healthy individuals, exhibit a specific serum metabolic profile (R[2 ]= 0.931; Q[2 ]= 0.873) characterized by statistically significant differences in the concentrations of a number of lipids, organic acids and amino acids. The metabolic profiles obtained for NSCLC patients and healthy individuals were also different to that obtained for BPD patients. A similar analysis performed to compare the serum metabolomic profile of NSCLC patients at early and advanced stages of the disease (R[2 ]= 0.779; Q[2 ]= 0.592) showed that disease evolution has also a reflection in the metabolic profile of patients. Furthermore, a logistic regression analysis allowed the identification of a specific combination of five metabolites (threonine, glutamine, lactate, choline and methanol) that enables the discrimination between healthy individuals and NSCLC patients with a 77,5% sensitivity and a 76,9% specificity (70% for all non-cancer samples).
    
    Conclusion:
    Our results highlight the potential of metabolomics by [1]H-NMR for identifying biological pathways involved in the onset and progression of NSCLC, thus providing a sensitive, specific, minimally invasive and easily implementable method in clinical practice for the early diagnosis of NSCLC and for the optimization of risk profile models. Acknowledgements: Spanish Ministerio de Economía y Competitividad (MINECO, SAF2011-28350), Centro de Investigación Príncipe Felipe and Fundación Mutua Madrileña for their economic support and Red de Biobancos de Valencia and Bruker BioSpin for technical contributions. This study was also supported by the ISCIII (RTICC, RD12/0036/0025).
    
    

    Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.